September 10, 2020

ProSciento Closes Growth Financing from 1315 Capital Read More »

September 1, 2020

ProSciento Appoints Stephen Mullennix as Chief Financial Officer Read More »


View Recent Webinar


February 3, 2021

Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients. Read More »

January 8, 2021

Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with NAFLD non-alcoholic fatty liver disease: results from two early phase randomized trials. Read More »

December 1, 2020

ProSciento’s State-of-the-Art Clinical Research Center for Metabolic Studies Read More »

Stay Connected

Would you like to receive updates from ProSciento?